Southwest Oncology Group trial SWOG-8814 (The Breast Cancer Intergroup of North America 0100) Kaplan-Meier disease-free survival and overall survival distributions for 1116 eligible patients at risk on the combined CAF plus tamoxifen groups (566, CAF-T; 550, CAFT) and 361 on tamoxifen alone. Panel A shows the disease-free survival for the combined CAF plus tamoxifen groups versus tamoxifen alone, log-rank P=0.002, stratified by number of positive nodes, hormone receptor status, and time from definitive surgery.. Panel B depicts the overall survival for the CAF plus tamoxifen versus tamoxifen comparison, stratified log-rank P=0.043. Panel C represents the disease-free survival for the CAFT versus CAF-T comparison, stratified log-rank P=0.055. Panel D shows the overall survival with 10-year estimates for the CAFT versus CAF-T comparison, stratified log-rank P=0.27. Ten-year survival estimates with 95% confidence intervals are also given.